Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ALDX |
---|---|---|
09:32 ET | 10070 | 3.305 |
09:34 ET | 917 | 3.3 |
09:36 ET | 2509 | 3.32 |
09:38 ET | 4610 | 3.28 |
09:39 ET | 1100 | 3.3 |
09:41 ET | 200 | 3.3 |
09:43 ET | 3675 | 3.26 |
09:45 ET | 200 | 3.275 |
09:48 ET | 4248 | 3.27 |
09:50 ET | 600 | 3.27 |
09:52 ET | 1270 | 3.275 |
09:54 ET | 6746 | 3.3 |
09:56 ET | 600 | 3.2801 |
09:57 ET | 1800 | 3.26 |
09:59 ET | 200 | 3.28 |
10:01 ET | 600 | 3.29 |
10:03 ET | 1978 | 3.29 |
10:06 ET | 1391 | 3.3 |
10:08 ET | 641 | 3.3 |
10:10 ET | 391 | 3.3 |
10:12 ET | 703 | 3.3 |
10:14 ET | 274 | 3.3 |
10:15 ET | 315 | 3.3 |
10:17 ET | 391 | 3.3096 |
10:19 ET | 1894 | 3.3 |
10:21 ET | 9290 | 3.305 |
10:24 ET | 1434 | 3.3069 |
10:26 ET | 515 | 3.31 |
10:28 ET | 376 | 3.31 |
10:30 ET | 215 | 3.31 |
10:32 ET | 518 | 3.309 |
10:33 ET | 1179 | 3.31 |
10:37 ET | 100 | 3.31 |
10:42 ET | 352 | 3.315 |
10:48 ET | 461 | 3.315 |
10:50 ET | 100 | 3.315 |
10:53 ET | 2036 | 3.31 |
10:55 ET | 100 | 3.305 |
11:00 ET | 422 | 3.305 |
11:09 ET | 3320 | 3.3 |
11:11 ET | 100 | 3.31 |
11:22 ET | 1753 | 3.3 |
11:24 ET | 1204 | 3.3 |
11:26 ET | 100 | 3.3 |
11:27 ET | 1572 | 3.29 |
11:31 ET | 2500 | 3.3 |
11:33 ET | 3535 | 3.31 |
11:44 ET | 2894 | 3.32 |
11:45 ET | 300 | 3.32 |
11:47 ET | 100 | 3.32 |
11:49 ET | 220 | 3.32 |
11:51 ET | 3628 | 3.34 |
11:58 ET | 172 | 3.35 |
12:03 ET | 407 | 3.3531 |
12:14 ET | 100 | 3.36 |
12:20 ET | 130 | 3.365 |
12:21 ET | 500 | 3.365 |
12:23 ET | 200 | 3.37 |
12:27 ET | 265 | 3.36 |
12:30 ET | 300 | 3.36 |
12:32 ET | 1483 | 3.3899 |
12:34 ET | 914 | 3.3701 |
12:38 ET | 100 | 3.375 |
12:41 ET | 666 | 3.3784 |
12:43 ET | 826 | 3.374 |
12:52 ET | 100 | 3.38 |
12:54 ET | 148 | 3.3709 |
12:56 ET | 357 | 3.36 |
12:57 ET | 200 | 3.36 |
12:59 ET | 1100 | 3.35 |
01:08 ET | 880 | 3.35 |
01:12 ET | 280 | 3.345 |
01:15 ET | 149 | 3.34 |
01:19 ET | 100 | 3.35 |
01:28 ET | 3374 | 3.37 |
01:30 ET | 100 | 3.365 |
01:33 ET | 108 | 3.365 |
01:35 ET | 100 | 3.365 |
01:39 ET | 1103 | 3.37 |
01:46 ET | 100 | 3.365 |
01:48 ET | 200 | 3.365 |
01:50 ET | 100 | 3.365 |
01:51 ET | 5363 | 3.3794 |
01:57 ET | 600 | 3.37 |
02:02 ET | 542 | 3.37 |
02:04 ET | 878 | 3.38 |
02:08 ET | 399 | 3.38 |
02:13 ET | 100 | 3.385 |
02:15 ET | 1200 | 3.39 |
02:18 ET | 100 | 3.385 |
02:20 ET | 200 | 3.385 |
02:24 ET | 160 | 3.3898 |
02:27 ET | 600 | 3.38 |
02:29 ET | 200 | 3.37 |
02:33 ET | 200 | 3.36 |
02:38 ET | 3556 | 3.36 |
02:40 ET | 2453 | 3.36 |
02:44 ET | 100 | 3.355 |
02:45 ET | 100 | 3.355 |
02:47 ET | 600 | 3.35 |
02:49 ET | 200 | 3.345 |
02:51 ET | 797 | 3.34 |
02:58 ET | 600 | 3.34 |
03:02 ET | 226 | 3.33 |
03:07 ET | 100 | 3.33 |
03:09 ET | 300 | 3.33 |
03:12 ET | 100 | 3.32 |
03:14 ET | 100 | 3.325 |
03:16 ET | 1285 | 3.335 |
03:18 ET | 300 | 3.34 |
03:20 ET | 300 | 3.335 |
03:21 ET | 200 | 3.335 |
03:23 ET | 417 | 3.335 |
03:25 ET | 1955 | 3.345 |
03:27 ET | 100 | 3.35 |
03:30 ET | 324 | 3.345 |
03:32 ET | 767 | 3.35 |
03:34 ET | 663 | 3.35 |
03:36 ET | 814 | 3.34 |
03:39 ET | 436 | 3.335 |
03:41 ET | 583 | 3.33 |
03:43 ET | 2423 | 3.325 |
03:45 ET | 1285 | 3.33 |
03:48 ET | 626 | 3.33 |
03:50 ET | 300 | 3.34 |
03:52 ET | 950 | 3.335 |
03:54 ET | 7021 | 3.335 |
03:56 ET | 3172 | 3.32 |
03:57 ET | 1431 | 3.33 |
03:59 ET | 8725 | 3.33 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Aldeyra Therapeutics Inc | 195.5M | -6.6x | --- |
Acrivon Therapeutics Inc | 193.3M | -2.1x | --- |
Biomea Fusion Inc | 199.5M | -1.5x | --- |
Greenwich Lifesciences Inc | 199.6M | -21.4x | --- |
Design Therapeutics Inc | 189.8M | -3.2x | --- |
Pyxis Oncology Inc | 187.9M | -2.2x | --- |
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $195.5M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 59.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.45 |
EPS | $-0.51 |
Book Value | $2.02 |
P/E Ratio | -6.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.